Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Net Income (2018 - 2025)

TELA Bio has reported Net Income over the past 8 years, most recently at $30.3 million for Q4 2025.

  • Quarterly results put Net Income at $30.3 million for Q4 2025, up 3.46% from a year ago — trailing twelve months through Dec 2025 was $470000.0 (down 23.58% YoY), and the annual figure for FY2025 was $470000.0, down 38.08%.
  • Net Income for Q4 2025 was $30.3 million at TELA Bio, up from -$8.6 million in the prior quarter.
  • Over the last five years, Net Income for TELA hit a ceiling of $30.3 million in Q4 2025 and a floor of -$13.6 million in Q4 2023.
  • Median Net Income over the past 5 years was -$10.4 million (2022), compared with a mean of -$6.2 million.
  • Biggest five-year swings in Net Income: soared 314.7% in 2024 and later plummeted 98.98% in 2025.
  • TELA Bio's Net Income stood at -$8.6 million in 2021, then decreased by 23.75% to -$10.6 million in 2022, then dropped by 28.36% to -$13.6 million in 2023, then surged by 314.7% to $29.2 million in 2024, then grew by 3.46% to $30.3 million in 2025.
  • The last three reported values for Net Income were $30.3 million (Q4 2025), -$8.6 million (Q3 2025), and -$9.9 million (Q2 2025) per Business Quant data.